Glenmark Life Sciences
Glenmark Life Sciences, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions, including North America, Europe, and Asia. Founded in 2013, the company has rapidly established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations, particularly in the therapeutic areas of cardiology, diabetes, and central nervous system disorders. With a commitment to quality and innovation, Glenmark Life Sciences offers a diverse portfolio of products that cater to both generic and branded markets. The company is recognised for its robust research and development capabilities, which have led to significant milestones in API production. As a subsidiary of Glenmark Pharmaceuticals, it has garnered a strong market position, contributing to the global healthcare landscape with its high-quality, cost-effective solutions.
DitchCarbon Score
How does Glenmark Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Life Sciences's score of 14 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Glenmark Life Sciences's reported carbon emissions
In 2023, Glenmark Life Sciences reported total carbon emissions of approximately 63,075,400 kg CO2e, comprising about 12,798,000 kg CO2e from Scope 1 and about 50,407,400 kg CO2e from Scope 2. This represents a significant reduction from 2022, where total emissions were about 76,679,000 kg CO2e, with Scope 1 emissions at approximately 26,879,000 kg CO2e and Scope 2 emissions at about 49,900,000 kg CO2e. Despite these reductions, Glenmark Life Sciences has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to focus on improving its emissions intensity, which was reported at approximately 69,480 kg CO2e per tonne of output in 2023. As Glenmark Life Sciences is headquartered in India, its commitment to reducing carbon emissions aligns with global trends in the pharmaceutical industry, where companies are increasingly prioritising sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 26,879,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 49,900,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Life Sciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
